A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain

201667 citationsJournal Articlehybrid Open Access

Authors

Naldemedine 0.2 mg once daily is the optimal dose for future confirmatory trials in OIC.

Good health and well-being

Published in: Pain Medicine

Volume 18, Issue 12, pp. 2350-2360

Field-Weighted Citation Impact: 7.28